永安药业(002365.SZ)：预计2025年净利润同比下降56.21%～70.56%

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) forecasts a significant decline in its 2025 annual performance, with net profit attributable to shareholders expected to drop by 56.21% to 70.56% compared to the previous year [1] Financial Performance - The projected net profit for 2025 is between 18.19 million yuan and 27.05 million yuan [1] - The net profit after deducting non-recurring gains and losses is expected to be a loss of 1.55 million yuan to 2.88 million yuan, compared to a profit of 26.76 million yuan in the same period last year [1] - Basic earnings per share are estimated to be between 0.0617 yuan and 0.0918 yuan [1] Market Conditions - The decline in performance is primarily attributed to a sluggish market environment and intense competition in the taurine market [1] - Both the production and sales volume, as well as the selling price of the main product taurine, have decreased compared to the same period last year [1]